secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2021-10-04T23:59:59+00:00
Accession:  0001787306-21-000021
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis submits NDA to FDA for roflumilast cream in plaque psoriasis
--------------------------------------------------------------------

- Submitted NDA for roflumilast cream (ARQ-151) to FDA for mild-to-severe plaque psoriasis.
- Indication covers adults and adolescents; submission date October 4, 2021.
- Roflumilast cream is a topical PDE4 inhibitor, a novel mechanism for psoriasis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/0001787306-21-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730621000021/arqt-20211004.htm
  HTML page:      https://secwatch.observer/filing/0001787306-21-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer